Schedule 13D ownership disclosure

CITY THERAPEUTICS, INC.

Common Stock, $0.0001 par value · CUSIP: 178782108

Event date: 2026-10-19

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • ARCH Venture Fund XII, L.P.Reported CIK 0001906837

    Shares: 13,692,507 · Class: 25.6%

  • ARCH Venture Partners XII, L.P.Reported CIK 0001979765

    Shares: 13,692,507 · Class: 25.6%

  • ARCH Venture Partners XII, LLCReported CIK 0001979548

    Shares: 13,692,507 · Class: 25.6%

  • Robert NelsenReported CIK 0001219042

    Shares: 13,692,507 · Class: 25.6%

  • Keith CrandellReported CIK 0001219039

    Shares: 13,692,507 · Class: 25.6%

  • Kristina BurowReported CIK 0001569248

    Shares: 13,692,507 · Class: 25.6%

  • Steven GillisReported CIK 0001229592

    Shares: 13,692,507 · Class: 25.6%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001193125-26-432028
Form type
SCHEDULE 13D
Filer
CITY THERAPEUTICS, INC.
CIK
CIK 2143850
Filed
Oct 26, 2026
Reporting period
Oct 19, 2026
Description
Schedule 13D beneficial ownership

Explore SEC Filings Hub